Search Videos and More
News
New Research Sheds Light on Why Tamoxifen May Lead to Higher Risk of Uterine Cancer
Since its introduction in the 1970s, tamoxifen has significantly improved survival rates for millions of patients with estrogen receptor–positive breast cancer.
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.
News
Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark
Breast cancer patients who participated in a remote weight loss intervention program lost an average of 4.7 percent of their baseline body weight after one year, while those in the education only control group gained an average 1 percent of their baseline weight, according to a new report from Dana-Farber Cancer Institute investigators.
News
New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science
Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.
News
Dana-Farber Research News 08.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 through July 31.
News
Dana-Farber Cancer Institute Unveils Groundbreaking Blood Test for Multiple Myeloma
Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions.Dana-Farber Research Publication, 8.1.2021
News
Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs Launch Precision Genomics Initiative for Pediatric Cancer
In a pioneering collaboration aimed at transforming pediatric cancer diagnostics and research, Dana-Farber Cancer Institute, Boston Children’s Hospital, and Broad Clinical Labs have announced the formation of BrightSeq — Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing — collaborative clinical research and testing initiative.
News
When Science Moves Mountains
How Dana-Farber Research Delivered New Medicines and Long-Range Hope for a Patient With Metastatic Breast Cancer
News
Dana-Farber Research News 08.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.
News
Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Results from this study show that already approved precision medicines have the potential benefit for children with FGFR-altered gliomas.
News
U.S. News & World Report Names Dana-Farber Brigham Cancer Center Among Nation’s Best for 2025-2026
Recognition marks a quarter of a century of excellence